Summary
2.32 -0.01(-0.34%)09/06/2024
Can-Fite Biopharma Ltd (CANF)
Can-Fite Biopharma Ltd (CANF)
Key Facts
1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
-0.34 | 4.50 | -14.23 | -10.04 | 8.16 | -17.44 | -90.49 | -99.72 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Trading Data | ||
Close | 2.32 | |
Open | 2.40 | |
High | 2.41 | |
Low | 2.20 | |
Volume | 103,380 | |
Change | -0.01 | |
Change % | -0.34 | |
Avg Volume (20 Days) | 70,222 | |
Volume/Avg Volume (20 Days) Ratio | 1.47 | |
52 Week Range | 1.81 - 4.69 | |
Price vs 52 Week High | -50.53% | |
Price vs 52 Week Low | 28.18% | |
Range | -3.33 | |
Gap Up/Down | 0.02 |
Fundamentals | ||
Market Capitalization (Mln) | 14 | |
EBIDTA | -8,180,000 | |
PE Ratio | 0.0000 | |
PEG Ratio | 0.0000 | |
WallStreet Target Price | 12.00 | |
Book Value | 0.0050 | |
Earnings Per Share | -3.0000 | |
EPS Estimate Current Quarter | -0.2600 | |
EPS Estimate Next Quarter | 0.0000 | |
EPS Estimate Current Year | -1.0900 | |
EPS Estimate Next Year | -1.0500 | |
Diluted EPS (TTM) | -3.0000 | |
Revenues | ||
Profit Marging | 0.0000 | |
Operating Marging (TTM) | -11.8323 | |
Return on asset (TTM) | -0.5315 | |
Return on equity (TTM) | -1.4249 | |
Revenue TTM | 743,000 | |
Revenue per share TTM | 0.3000 | |
Quarterly Revenue Growth (YOY) | -0.2130 | |
Quarterly Earnings Growth (YOY) | 0.0000 | |
Gross Profit (TTM) | 810,000 |
Dividends | ||
Dividend Share | 0.0000 | |
Dividend Yield | ||
Valuations | ||
Trailing PE | 0.0000 | |
Forward PE | 0.0000 | |
Price Sales (TTM) | 0.0000 | |
Price Book (MRQ) | 1.6787 | |
Revenue Enterprise Value | 2.5253 | |
EBITDA Enterprise Value | -0.2294 | |
Shares | ||
Shares Outstanding | 4,990,430 | |
Shares Float | 1,496,709,297 | |
Shares Short | 0 | |
Shares Short (Prior Month) | 0 | |
Shares Ratio | 0.00 | |
Short Outstanding (%) | 0.00 | |
Short Float (%) | 0.01 | |
Insider (%) | 0.00 | |
Institutions (%) | 4.49 |
08/29 08:15 EST - globenewswire.com
Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
RAMAT GAN, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for H1 2024.
Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
RAMAT GAN, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for H1 2024.
08/09 09:00 EST - accesswire.com
OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / August 9, 2024 / RedChip Companies will air interviews with OS Therapies Inc. (NYSE American:OSTX) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 10, at 7 p.m.
OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / August 9, 2024 / RedChip Companies will air interviews with OS Therapies Inc. (NYSE American:OSTX) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 10, at 7 p.m.
08/08 19:01 EST - globenewswire.com
Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
RAMAT GAN, Israel, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,857,143 American Depositary Shares (ADSs), having an exercise price of $1.75 per ADS, issued by Can-Fite in January 2023 and November 2023. The ADSs representing ordinary shares issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form F-3 (File No. 333-276000) and Form F-1 (File No. 333-269485). The closing of the offering is expected to occur on or about August 12, 2024, subject to satisfaction of customary closing conditions.
Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
RAMAT GAN, Israel, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,857,143 American Depositary Shares (ADSs), having an exercise price of $1.75 per ADS, issued by Can-Fite in January 2023 and November 2023. The ADSs representing ordinary shares issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form F-3 (File No. 333-276000) and Form F-1 (File No. 333-269485). The closing of the offering is expected to occur on or about August 12, 2024, subject to satisfaction of customary closing conditions.
07/29 07:00 EST - globenewswire.com
Can-Fite Provides Namodenoson Patent Update
Broad Protection of Namodenoson is expected till at least 2044 PETACH TIKVA, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced an update related to the intellectual property (IP) status of its lead drug candidate Namodenoson, currently being developed for advanced liver cancer, pancreatic cancer and MASH.
Can-Fite Provides Namodenoson Patent Update
Broad Protection of Namodenoson is expected till at least 2044 PETACH TIKVA, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced an update related to the intellectual property (IP) status of its lead drug candidate Namodenoson, currently being developed for advanced liver cancer, pancreatic cancer and MASH.
07/17 07:00 EST - globenewswire.com
Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8
RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, invites investors to a webinar on August 8, 2024, at 4:15 p.m. ET.
Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8
RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, invites investors to a webinar on August 8, 2024, at 4:15 p.m. ET.
07/11 07:00 EST - globenewswire.com
Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
PETACH TIKVA, Israel, July 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation for its drug candidate Namodenoson in the treatment of pancreatic carcinoma.
Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
PETACH TIKVA, Israel, July 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation for its drug candidate Namodenoson in the treatment of pancreatic carcinoma.
06/24 07:00 EST - businesswire.com
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that company scientists came up with breakthrough findings showing that the anti-cancer and protective effects in the liver are conferred via the signalling protein adiponectin. This very important positive cytokine plays a pivotal role in regulating.
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that company scientists came up with breakthrough findings showing that the anti-cancer and protective effects in the liver are conferred via the signalling protein adiponectin. This very important positive cytokine plays a pivotal role in regulating.
06/10 07:00 EST - businesswire.com
Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it received an approval from the Institutional Review Board (IRB) of Rabin Medical Center, a leading medical institution in Israel where the study will be conducted. The approved protocol has been submitted now to the Ministry of Health (MOH). “T.
Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it received an approval from the Institutional Review Board (IRB) of Rabin Medical Center, a leading medical institution in Israel where the study will be conducted. The approved protocol has been submitted now to the Ministry of Health (MOH). “T.
06/05 07:00 EST - businesswire.com
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study
RAMAT GAN, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced an update on the status of its oncological lead drug candidate, Namodenoson in the treatment of advanced liver cancer. The Phase 3 pivotal study now has 31 recruiting medical centers in Europe, Israel and the US. Namodenoson has Orphan Drug status with bo.
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study
RAMAT GAN, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced an update on the status of its oncological lead drug candidate, Namodenoson in the treatment of advanced liver cancer. The Phase 3 pivotal study now has 31 recruiting medical centers in Europe, Israel and the US. Namodenoson has Orphan Drug status with bo.
05/29 07:00 EST - businesswire.com
Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases
RAMAT-GAN, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today reported that the International Journal of Molecular Sciences published a scientific review by independent scientists summarizing >50 publications from scientists all over the world stating that piclidenoson and namodenoson have a positive effect on heart disea.
Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases
RAMAT-GAN, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today reported that the International Journal of Molecular Sciences published a scientific review by independent scientists summarizing >50 publications from scientists all over the world stating that piclidenoson and namodenoson have a positive effect on heart disea.
05/27 07:00 EST - businesswire.com
Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024
PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that its VP of Business Development, Dr. Sari Fishman, will hold 23 partnering meetings with Biotech & Pharma companies, who showed interest in partnering with Can-Fite. The meetings will take place during the Bio International Convention 2024 in.
Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024
PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that its VP of Business Development, Dr. Sari Fishman, will hold 23 partnering meetings with Biotech & Pharma companies, who showed interest in partnering with Can-Fite. The meetings will take place during the Bio International Convention 2024 in.
05/23 07:00 EST - businesswire.com
Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6
RAMAT GAN, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, is pleased to invite investors to a webinar on June 6, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Can-Fite CEO Motti Farbstein and Executive Chairperson and Chief Scientific Officer Pnina Fishman, PhD, who will share insight int.
Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6
RAMAT GAN, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, is pleased to invite investors to a webinar on June 6, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Can-Fite CEO Motti Farbstein and Executive Chairperson and Chief Scientific Officer Pnina Fishman, PhD, who will share insight int.
05/13 07:00 EST - businesswire.com
Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study
RAMAT GAN, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that it held a conference for 75 oncologists and coordinators who are conducting the pivotal Phase 3 advanced liver cancer study, to accelerate patient enrolment. The participants have been presented with the drug chemical and biological profile and the s.
Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study
RAMAT GAN, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that it held a conference for 75 oncologists and coordinators who are conducting the pivotal Phase 3 advanced liver cancer study, to accelerate patient enrolment. The participants have been presented with the drug chemical and biological profile and the s.
05/10 09:00 EST - accesswire.com
Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE American:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 11, at 7 p.m.
Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE American:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 11, at 7 p.m.
05/06 07:00 EST - businesswire.com
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it received a Notice of Allowance from the European Patent Office for its patent application titled “An A3 Adenosine Receptor Ligands For Use in Treatment of a Sexual Dysfunction”. This invention addresses the use of the CF602 drug candidate as an oral.
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it received a Notice of Allowance from the European Patent Office for its patent application titled “An A3 Adenosine Receptor Ligands For Use in Treatment of a Sexual Dysfunction”. This invention addresses the use of the CF602 drug candidate as an oral.
04/25 07:00 EST - businesswire.com
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it published an article in the Experimental and Therapeutic Medicine Journal, titled “Long-term complete response to namodenoson in liver cancer with Child-Pugh B cirrhosis: A case report” (Link). The patient participated in the Phase II Liver Cancer.
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced it published an article in the Experimental and Therapeutic Medicine Journal, titled “Long-term complete response to namodenoson in liver cancer with Child-Pugh B cirrhosis: A case report” (Link). The patient participated in the Phase II Liver Cancer.
04/15 07:00 EST - businesswire.com
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that Biomedicines published an article titled “Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Hepatocellular Carcinoma (HCC)”. Biomedicines is a highly reputable journal that publishes articles on clinical.
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that Biomedicines published an article titled “Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Hepatocellular Carcinoma (HCC)”. Biomedicines is a highly reputable journal that publishes articles on clinical.
04/03 07:00 EST - businesswire.com
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
RAMAT GAN, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), for the Company's.
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
RAMAT GAN, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), for the Company's.
04/01 07:00 EST - newsfilecorp.com
Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV
Ramat Gan, Israel--(Newsfile Corp. - April 1, 2024) - Can-Fite BioPharma, Ltd. (NYSE American: CANF) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024.
Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV
Ramat Gan, Israel--(Newsfile Corp. - April 1, 2024) - Can-Fite BioPharma, Ltd. (NYSE American: CANF) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024.
03/28 07:00 EST - businesswire.com
Can-Fite Reports 2023 Financial Results and Clinical Update
RAMAT GAN, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended December 31, 2023. Recent Clinical & Development Milestones Achieved Namodenoson Drug Candidate: Ewopharma recently acquired marketing rights for Namodenoson in the treatment of pancr.
Can-Fite Reports 2023 Financial Results and Clinical Update
RAMAT GAN, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended December 31, 2023. Recent Clinical & Development Milestones Achieved Namodenoson Drug Candidate: Ewopharma recently acquired marketing rights for Namodenoson in the treatment of pancr.